PacBio Q2 FY26 net loss widens to $44.7 million; revenue slips 2% to $39 million
PACB•Second-quarter results
Pacific Biosciences posted Q2 2026 revenue of $39 million, down 2% year over year; consumables rose 6% to $20.1 million.
GAAP net loss widened to $44.7 million while GAAP net loss per share held at $0.14.
GAAP gross margin fell 5 percentage points to 32% due to higher compute and memory costs, Vega manufacturing transition costs, and lower Revio average selling prices.
Instrument placements and outlook
Revio system placements climbed to 20, while Vega placements slipped to 26; annualized Revio pull-through per system eased to about $202,000.
The company forecast 2026 revenue of $155 million to $165 million. It also began a global SPRQ-Nx rollout, listing whole-genome sequencing at $345 per genome.
